Latest

Learn how antibiotic-resistant UTI testing identifies ESBL, CRE, resistance genes, and antibiotic susceptibility, and how culture results guide treatment and follow-up.

Antibiotic-Resistant UTI Test: ESBL, CRE, Resistance Markers, and Culture Meaning

Learn what asymptomatic bacteriuria means, how a positive urine culture without UTI symptoms is interpreted, and when screening, treatment, or follow-up matters.

Asymptomatic Bacteriuria Test: Positive Culture Without Symptoms and When It Matters

Learn how bacteria in urine are interpreted using urinalysis, culture, colony count, symptoms, and sample quality, including when contamination or follow-up testing matters.

Bacteria in Urine Test: UTI, Contamination, Colony Count, and Culture Follow-Up

Learn how a catheter urine culture helps diagnose catheter-associated UTI, how samples are collected, and what colony counts, pyuria, resistance, and positive results mean.

Catheter Urine Culture Test: Catheter-Associated UTI and Culture Meaning

Learn how a chlamydia and gonorrhea urine NAAT works, how to collect first-catch urine, what positive or negative results mean, and when follow-up testing is needed.

Chlamydia and Gonorrhea Urine NAAT Test: STI Screening, Positive Result, and Meaning

Learn how to collect a clean-catch urine culture, reduce contamination, handle the sample correctly, and understand mixed flora, colony counts, repeat testing, and accurate results.

Clean-Catch Urine Culture Test: Sample Collection, Contamination, and Accurate Results

Diagnostics

Home Diagnostics Page 87

Learn how liquid biopsy and ctDNA testing find tumor mutations, guide targeted therapy, assess resistance and MRD, and why negative or low-level plasma results need careful interpretation.

Liquid Biopsy Cancer Test: ctDNA, Tumor Mutations, and Results

Learn how Lynch syndrome testing for MLH1, MSH2, MSH6, PMS2, and EPCAM works, how tumor screening differs from germline testing, and what positive, negative, and uncertain results mean.

Lynch Syndrome Genetic Test: MLH1, MSH2, MSH6, PMS2, EPCAM, and Results

Learn how MEN1 genetic testing confirms multiple endocrine neoplasia type 1, who should be tested, what positive and negative results mean, and how surveillance protects patients and relatives.

MEN1 Genetic Test: Multiple Endocrine Neoplasia Type 1 and Results

Learn how MET exon 14 skipping testing finds an actionable lung cancer driver, why DNA and RNA methods differ, and how positive, negative, plasma, treatment, and resistance results are interpreted.

MET Exon 14 Skipping Test: Lung Cancer, Targeted Therapy, and Results

Learn how MSI and dMMR testing guides cancer immunotherapy and Lynch syndrome evaluation, including IHC patterns, PCR, NGS, reflex testing, and discordant results.

Microsatellite Instability (MSI) and Mismatch Repair Deficiency (dMMR) Test: Cancer Immunotherapy,...

Learn how minimal residual disease (MRD) tests detect tiny amounts of cancer, what positive and negative results mean, and how testing may guide recurrence risk and follow-up.

Minimal Residual Disease (MRD) Test: Cancer Recurrence Risk and Results

Learn what an MLH1 genetic test shows, how results relate to Lynch syndrome and colon cancer risk, and what positive, negative, and uncertain findings mean for care and family.

MLH1 Genetic Test: Lynch Syndrome, Colon Cancer Risk, and Results

Learn how the MPL mutation test helps evaluate high platelets and myeloproliferative neoplasms, including positive, negative, VAF, treatment, and follow-up results.

MPL Mutation Test: Myeloproliferative Neoplasm, Platelets, and Results

Learn what an MSH2 genetic test shows, how results relate to Lynch syndrome and colon cancer risk, and what positive, negative, and uncertain findings mean for care and family.

MSH2 Genetic Test: Lynch Syndrome, Colon Cancer Risk, and Results

Learn what an MSH6 genetic test shows, how results relate to Lynch syndrome and colon cancer risk, and what positive, negative, and uncertain findings mean for care and family.

MSH6 Genetic Test: Lynch Syndrome, Colon Cancer Risk, and Results

Learn how MUTYH genetic testing identifies polyposis risk, why two variants differ from one, and what positive, negative, carrier, and uncertain results mean.

MUTYH Genetic Test: Colon Polyposis, Cancer Risk, and Results

Understand MYC rearrangement test results in lymphoma and leukemia, including FISH, double-hit and triple-hit findings, double expression, prognosis, and treatment implications.

MYC Rearrangement Test: Lymphoma, Leukemia, and Results

Learn how MYD88 mutation testing supports Waldenström macroglobulinemia and lymphoma diagnosis, including L265P results, methods, treatment relevance, and limits.

MYD88 Mutation Test: Waldenstrom Macroglobulinemia, Lymphoma, and Results

Learn how NPM1 mutation testing classifies AML, affects prognosis, and supports sensitive MRD monitoring, including positive, negative, VAF, and treatment results.

NPM1 Mutation Test: AML Prognosis, Leukemia Genetics, and Results

Understand NRAS mutation test results in melanoma and colorectal cancer, including extended RAS coverage, anti-EGFR resistance, treatment relevance, and test limits.

NRAS Mutation Test: Melanoma, Colon Cancer, and Results

Learn how NTRK fusion testing finds tumor-agnostic targets, compares RNA NGS, DNA NGS, IHC, and FISH, and guides TRK inhibitor treatment and resistance testing.

NTRK Fusion Test: Cancer Targeted Therapy, Gene Fusion, and Results

1...868788...137 Page 87 of 137